Compare Boston Scientific Corporation (BSX) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Nebius Group NV — how do they compare? Boston Scientific Corporation trades at $51.36 (market cap $74.19B), while Nebius Group NV trades at $243.61 (market cap $49.06B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Nebius Group NV is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | NBIS | |
|---|---|---|
Market Cap | $74.19B | $49.06B |
Sector | Health | Technology |
52-Week High | $108.14 | $286.69 |
52-Week Low | $42.63 | $64.06 |
Enterprise Value | $86.27B | $49.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
NBIS stock surged 23.65% to $227.66 on strong Q2 2026 earnings that beat expectations, extending its AI cloud rally. The company shows explosive revenue growth with 2026 projections indicating $878 million revenue and $817 million net income, though current valuations remain elevated with a P/E of 74.61. Technical indicators show bearish momentum despite the recent price surge, with support at $190 and resistance at $196.
The outlook remains positive given strong analyst consensus (89% buy ratings) and a $248.73 price target, but risks include Michael Burry's short position, execution challenges in capacity expansion, and premium valuation multiples that leave little room for error in meeting growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
